Navigation Links
OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer

Webcast at 7:10 p.m. Eastern Time Today

BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the final results of a Randomized Phase 2 Trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Analyses indicated a survival benefit in patients treated with OGX-011 in combination with docetaxel compared to docetaxel alone - the current standard care for patients with advanced prostate cancer:

    1)  The median overall survival in patients with advanced metastatic
        prostate cancer who were treated with OGX-011 plus docetaxel in a
        randomized Phase 2 trial was 23.8 months compared to 16.9 months for
        patients treated with docetaxel alone -- a 6.9 month observed
        survival advantage for the OGX-011 arm.

    2)  The unadjusted hazard ratio (HR), a measure used to compare the death
        rates between treatment groups, was 0.61, representing a 39% lower
        rate of death for patients treated with OGX-011.

    3)  A prospectively defined multivariate analysis indicated that the
        significant predictors of overall survival were treatment arm,
        performance status, and presence of metastases other than in bone or
        lymph nodes. Patients treated with OGX-011 had a rate of death 51%
        lower than patients treated with docetaxel alone (HR=0.49;
        p=0.012). Additional exploratory analyses found that the
        lower rate of death was associated with the effect of OGX-011
        treatment even when varying amounts of chemotherapy were administered
        (i.e. OGX-011 treatment resulted in a lower rate of death when
        compared to the control arm for patients receiving 6 or less cycles
        of chemotherapy as well as for patie
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
2. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
3. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
4. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
5. OncoGenex Reports First Quarter Financial Results
6. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
7. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
8. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
9. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
10. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
11. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Post Your Comments:
(Date:8/28/2014)... Exciting new work by a Florida State University ... that can take your temperature, emit white light, and ... the molecule looks like a butterfly. , Biwu Ma, ... Engineering in the FAMU-FSU College of Engineering, created the ... has continued to discover that his creation has many ...
(Date:8/28/2014)... 2014 PrimeSource Building Products, Inc., ... SoundConnect to support their communication needs ... and web conferencing platform GlobalMeet powered by SoundConnect. ... needs. SoundConnect delivers award winning “results driven” ... Products will be utilizing GlobalMeet powered by ...
(Date:8/27/2014)... 27, 2014 Green & Grow Inc. ... B funding and secured Otter Capital as a significant ... accelerate commercialization of GGI’s Agriplier™ technology, building on recent ... , “Since our first meeting, we have been impressed ... product space,” said Alan Sobba, President and CEO of ...
(Date:8/27/2014)... --  MSC , a healthcare performance improvement company advancing ... of Mary Beth Loesch to President and ... preparing companies for rapid growth and market expansion, Loesch ... Corporate Development and Healthcare. In that role, she oversaw ... as corporate strategy and marketing. Previously, Loesch served as ...
Breaking Biology Technology:Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3MSC names Mary Beth Loesch President and CEO 2
... , ... Services, Inc. Is Pleased To Announce The Launch Of Its New And Improved Website. ... A More User-Friendly Design Layout To Enhance Functionality And Navigation. The Site Also Offers ... Sciences And Lab Operations. , ...
... , OMAHA, Neb., Aug. 6 Transgenomic Inc. (OTC Bulletin Board: TBIO) announces ... Transgenomic Inc. Second Quarter 2009 Earnings Release, ... Wednesday, August 12, 2009 @ 5:00 p.m. Eastern, Where: ... log on to the web at the, ...
... Oncothyreon Inc. (Nasdaq: ONTY ) (TSX:ONY), a ... products for the treatment of cancer, today announced that ... end 2009 financial results on Wednesday, August 12, 2009 ... Following the release, Oncothyreon,s management expects to discuss these ...
Cached Biology Technology:One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions 2Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast 2
(Date:8/28/2014)... The Entomological Society of America (ESA) is pleased to ... Honorary Member of the Society. Honorary Membership acknowledges those ... through significant involvement in the affairs of the Society ... honor are selected by the ESA Governing Board and ... will be honored at the Awards Ceremony at Entomology ...
(Date:8/28/2014)... This news release is available in German . ... fresh water fish, owes its name to a striking pattern ... cell types, black cells, reflective silvery cells, and yellow cells ... fish and arrange as a multilayered mosaic to compose the ... all three cell types have to interact to form proper ...
(Date:8/28/2014)... A Mayo Clinic researcher and his collaborators have developed ... enhance the process of re-engineering cells for biomedical investigation. ... biology methods to aid stem cell engineering. Details of ... described in two back-to-back papers in the journal ... range of uses for all types of cell-based investigations ...
Breaking Biology News(10 mins):Fred Baxendale selected as Honorary Member of the Entomological Society of America 2How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3New tool aids stem cell engineering for medical research 2
... NEW YORK (Feb. 29, 2012)Exposure to lead wreaks havoc ... and reduced potential for learning. But the precise mechanism ... has largely remained unknown. New research led by ... of Environmental Health Sciences at Columbia University Mailman School ...
... New Orleans, LA Research led by Nicolas Bazan, MD, ... Excellence at LSU Health Sciences Center New Orleans, has found ... of experimental stroke. Dr. Bazan was issued a patent on ... crosses the blood-brain barrier. The findings are published in the ...
... of global scientists, led by researchers at Intermountain Medical Center ... accurate way to administer warfarin, one of the most commonly ... As part of a worldwide study, the research team ... data with a mathematical model to help physicians more accurately ...
Cached Biology News:In what ways does lead damage the brain? 2LSUSHC research identifies new experimental drug for stroke 2Researchers find safer way to use common but potentially dangerous medication 2Researchers find safer way to use common but potentially dangerous medication 3
... The H2OBIT is a fully licensed, high throughput, ... processing of up to 24 microplates. This equates ... plates. ,A robotic arm rapidly transfers a ... in temperature ramping times that are considerably faster ...
... Dideoxycytidine Dideoxycytidine is a cytidine analog that ... retroviral activity. Immunogen: Chemical / ... The specificity of the ddC antiserum was ... of ddC to moles of ddC analog at ...
... series of Class II Biological Safety ... certification to the world's highest safety ... the cabinets cannot be adjusted out ... low noise and arm rest ensure ...
... HM-4000 Multidizer is designed with a variety ... rotating - all in one unit. Shake, ... independently operating compartments allow for hybridization and ... motion , The upper chamber uses ...
Biology Products: